ストックスクリーナーアプリを入手
0.9245
0.49%
0.0045
アフターアワーズ：
.92
-0.0045
-0.49%
Mira Pharmaceuticals Inc (MIRA) 最新ニュース
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan
Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan
Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News
Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies - Moomoo
MIRA Reports Positive Preclinical Data for SKNY-1 Program - TipRanks
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) reports promising SKNY-1 preclinical pharmacokinetic and behavioral data - Stock Titan
MIRA's obesity-and-addiction drug shows brain and liver exposure - Stock Titan
MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan
MIRA Q3 2025 Earnings: EPS Beats Estimates by 26.47% as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Miss Report - dars.gov.et
What's going on with MIRA Pharma stock Tuesday? - MSN
MIRAMira Pharmaceuticals Inc Options - Finviz
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt - Moomoo
MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MacPherson Edward Cloustonmoomoo - Moomoo
MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Growth Benchmark - marketscreener.com
MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index - marketscreener.com
Price to earnings forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
Price to sales forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC - Black Hills Pioneer
MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S) - TradingView
MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S) - TradingView
MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S) - TradingView
K6S Forecast — Price Target — Prediction for 2027 - TradingView
MIRA Forecast — Price Target — Prediction for 2027 - TradingView
MIRA Flat at Open - Baystreet.ca
MIRA Pharmaceuticals (NASDAQ:MIRA) Reports Positive Preclinical Data for Mira-55 in Chronic Inflammatory Pain - grafa.com
Mira Pharmaceuticals reports preclinical data on pain drug candidate - Investing.com
MIRA Pharmaceuticals Advances Mira-55 for Chronic Pain Relief - GuruFocus
Mira Pharmaceuticals reports preclinical data on pain drug candidate By Investing.com - Investing.com Australia
MIRA Unveils Differentiated Preclinical Data for Mira-55 - TipRanks
MIRA’s Mira-55 eases anxiety in preclinical tests, unlike THC - Stock Titan
MIRA reports preclinical Mira-55 data showing distinct mechanism, anxiolytic activity vs THC - TradingView
MIRA Pharmaceuticals (NASDAQ: MIRA) highlights differentiated Mira-55 preclinical profile vs. THC - Stock Titan
Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy - ACCESS Newswire
MIRA Technical Analysis | Trend, Signals & Chart Patterns - ChartMill
Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Mira Pharmaceuticals Inc (MIRA) Institutional Confidence - TradingKey
Mira Pharmaceuticals Inc (MIRA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Mira Pharmaceuticals Inc (MIRA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mira Pharmaceuticals Inc (MIRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MIRA Pharmaceuticals submits Phase 2a trial for Ketamir-2 - grafa.com
MIRA Pharmaceuticals submits Phase 2a trial protocol for CIPN By Investing.com - Investing.com South Africa
MIRA Pharmaceuticals submits Phase 2a trial protocol for CIPN - Investing.com UK
MIRA Advances Ketamir-2 Into FDA-Accepted Phase 2a Trial - TipRanks
0.33%
1.23%
大文字化:
|
ボリューム (24 時間):